Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07531316 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers

A Phase 1 study, sponsored by Virginia Commonwealth University.

Not yet
Registry status
Phase 1
Development phase
60
Enrollment target

NCT07531316: Clinical Trial Phase 1 study, sponsored by Virginia Commonwealth University.

NCT07531316 is a Phase 1 study that has not yet begun recruiting, run by Virginia Commonwealth University. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07531316, a Phase 1 study, has not yet begun recruiting, sponsored by Virginia Commonwealth University.

NOT YET RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target

Study Summary

The goal of this study is to do follow-up safety testing and how well people are able tolerate an experimental (not FDA approved) medication . This study is seeking non-illicit drug using adults to test the medication. Results of this study will help us to develop future studies to test the medication with people who use substances.

Primary Outcome

Adverse event data will be compiled for VVZ-2471 and placebo cohorts and presented as summary statistics.

Interventions

  • DRUG Placebo pills for 14-day intervention
  • DRUG VVZ-2471 for 14-day intervention

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-07-15
Est. Completion 2031-12-30
Phase Phase 1
Virginia Commonwealth University

558 total trials

What is known before NCT07531316 opens enrollment

NCT07531316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Placebo pills for 14-day intervention is the first listed.

NCT07531316 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07531316 about?

NCT07531316 is a clinical study titled "Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers". The goal of this study is to do follow-up safety testing and how well people are able tolerate an experimental (not FDA approved) medication . This study is seeking non-illicit drug using adults to test the medication. Results of this study will help us to develop future studies to test the medicati...

What is the current status of trial NCT07531316?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-07-15. Estimated completion is 2031-12-30.

What interventions are being tested in trial NCT07531316?

The interventions under investigation include: Placebo pills for 14-day intervention (DRUG), VVZ-2471 for 14-day intervention (DRUG).

Who is sponsoring clinical trial NCT07531316?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07531316's enrollment target sits among peer trials

60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07531316, the US trial registry maintained by the National Library of Medicine. NCT07531316 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.